$9.49
+0.10 (+1.06%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VIR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
22 interventional · 1 expanded access · 10 with posted results
Held by 14 tracked-famous managers (Point72 Asset Management, L.P., Hudson Bay Capital Management LP, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, +9 more) · FINRA short interest 12.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.NCT05461170Proportion of participants with undetectable HDV RNA (< limit of detection [LOD]) or ≥ 2 log10 decrease in HDV RNA from baseline and alanine aminotransferase (ALT) normalization (ALT < upper limit of normal [ULN]) at Week 24Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: VIR-2218, VIR-3434, NRTI | Hepatitis D, Chronic | 95 | Nov 2031 | ≤ 1,929 d | 2026-06-26 |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsNCT06960395Primary Safety Objectives (Parts 1 and 3)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: VIR-5525, Pembrolizumab | Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR | 450 | Aug 2029 | ≤ 1,108 d | 2026-04-13 |
| To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersNCT05356741Incidence of dose-limiting toxicity - Part 1 and Part 2Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: VIR-5818, pembrolizumab | Locally Advanced or Metastatic HER2-Expressing Cancers | 645 | Apr 2028 | ≤ 620 d | 2026-08-19 |
| Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerNCT05997615Part 1 and 3a: Number of participants with treatment-emergent Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: VIR-5500 · Combination product: ARSI | Hormone-refractory Prostate Cancer | 437 | 2027-09-29 | in 406 d | 2026-06-04 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionNCT06903338HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Tobevibart, Elebsiran | Viral Hepatitis | 124 | 2026-12-31 | in 134 d | 2026-04-08 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Tobevibart, Elebsiran, Bulevirtide | Viral Hepatitis | 150 | Dec 2026 | ≤ 134 d | 2026-07-13 |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Tobevibart, Elebsiran, Bulevirtide | Viral Hepatitis | 100 | Nov 2026 | ≤ 103 d | 2026-01-16 |
| Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434NCT05484206Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: VIR-2218, VIR-3434 | Hepatic Impairment, Cirrhosis | 144 | 2026-09-25 | in 37 d | 2025-06-13 |
| Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionNCT04856085Proportion of participants with treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: VIR-2218, VIR-3434, PEG-IFNα | Hepatitis B, Chronic | 244 | 2026-03-16actual | — | 2026-04-23 |
| A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218NCT05844228Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and its metabolite AS(N-1)3'VIR-2218Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: VIR-2218 | Renal Impairment | 28 | 2025-03-01actual | — | 2025-06-13 |
| A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionNCT05612581results2025-11-26STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of TreatmentNon-randomized · Open-label · TreatmentStudy Protocol: PREVAIL ↗ · Study Protocol: STRIVE ↗ · Study Protocol: THRIVE ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: VIR-3434, VIR-2218, TDF, PEG-IFNα | Hepatitis B, Chronic | 33 | 2024-10-15actual | — | 2026-02-09 |
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionNCT04412863results2026-04-16Number of Subjects With Adverse Events as Assessed by CTCAE v5.0Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: VIR-2218, pegylated interferon-alfa 2a | Chronic Hepatitis B | 84 | 2024-03-25actual | — | 2026-04-16 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza ANCT05567783results2024-09-19Percentage of Participants With Protocol-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])Randomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: VIR-2482 1200 mg did not demonstrate efficacy versus placebo in the primary analysis of the primary endpoint | Biological: VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo | Influenza A | 2,977 | 2023-05-05actual | — | 2024-09-19 |
| Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)NCT05280717results2024-09-19Part A (Treatment Arms 1 and 2): Area Under the Serum Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC[D1 to 29]) Following Administration of SotrovimabRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Part C cohort 1 was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes. | Biological: sotrovimab, sotrovimab, sotrovimab, sotrovimab, sotrovimab, sotrovimab, sotrovimab | Covid19 | 316 | 2023-04-05actual | — | 2024-09-19 |
| VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy VolunteersNCT04725877Number of participants with any treatment-emergent adverse events (AEs)Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: VIR-1111 · Drug: Placebo | HIV I Infection | 27 | 2022-12-05actual | — | 2023-02-27 |
| Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus InfectionNCT04423393results2024-10-08Number of Participants With Treatment-emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: VIR-3434 · Other: Placebo | Chronic Hepatitis B | 113 | 2022-10-24actual | — | 2024-10-08 |
| Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.NCT04913675results2023-05-26Main Study: Percentage of Participants Who Had Progression of Coronavirus Disease 2019 (COVID-19) Through Day 29 by Hospitalization >24 Hours or Death Due to Any Cause (Weekly and Daily Imputation)Randomized · Open-label · TreatmentStudy Protocol: Main Study ↗ · Study Protocol: Safety Substudy ↗ · Statistical Analysis Plan: Safety Substudy ↗ · Statistical Analysis Plan: Main Study ↗ | Phase 3 | Terminatedsponsor's stated reason: The safety sub-study was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes | Biological: sotrovimab, sotrovimab, sotrovimab, sotrovimab, Sotrovimab, Sotrovimab, Sotrovimab | Covid19 | 1,065 | 2022-07-19actual | — | 2024-03-07 |
| Study of VIR-2482 in Healthy VolunteersNCT04033406Number of participants with treatment-emergent adverse events.Randomized · Quadruple-masked · Prevention | Phase 1 | Completed | Drug: VIR-2482, Placebo | Influenza A | 100 | 2021-11-01actual | — | 2022-06-09 |
| A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian ParticipantsNCT04988152results2024-06-07Part 1: Maximum Observed Serum Concentration (Cmax) of Sotrovimab Through Day 29Randomized · Single-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: sotrovimab, sotrovimab · Other: Placebo to Biologic, Placebo to Biologic | Covid19 | 48 | 2021-09-02actual | — | 2024-06-07 |
| Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19NCT04779879results2022-11-10Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Sotrovimab (Gen1), Sotrovimab (Gen2), Sotrovimab (Gen2) | Covid19 | 354 | 2021-08-20actual | — | 2023-05-03 |
| VIR-7831 for the Early Treatment of COVID-19 in OutpatientsNCT04545060results2022-11-07Number of Participants Who Had Progression of COVID-19 Through Day 29Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Biological: VIR-7831 (sotrovimab) · Drug: Placebo | Covid19 | 1,057 | 2021-04-08actual | — | 2022-11-07 |
| Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis BNCT03672188results2021-12-13Incidence of Adverse Events (AEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: VIR-2218, Placebo | Chronic Hepatitis B | 82 | 2020-09-03actual | — | 2021-12-13 |
| Sotrovimab Expanded Access Treatment Protocol (COVID-19)NCT05235347expanded access | — | No longer available | Biological: Sotrovimab | Covid19 | — | — | — | 2022-11-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19